8-K: Cadrenal Therapeutics Upsizes ATM Offering by $1.77M

Cadrenal Therapeutics, Inc. announced an update to its At-the-Market offering program, making available up to an additional $1.77 million in common stock.

Summary

• Cadrenal Therapeutics, Inc. filed a prospectus supplement on December 23, 2025, for an At-the-Market (ATM) offering program.
• The program allows for the offer and sale of up to an additional $1,770,028 of common stock.
• H.C. Wainwright & Co., LLC will act as the sales agent, receiving a 3.0% commission on gross sales.
• As of December 23, 2025, the company has already sold an aggregate of $10,005,300 of common stock under the existing ATM Agreement, which was dated March 11, 2024.
• The company retains discretion over the timing, volume, and minimum price of sales and is not obligated to sell any shares.

Sentiment

Score: 6

Explanation: The filing indicates a routine capital-raising activity through an existing ATM program. While it provides funding flexibility (positive), it also implies potential future dilution for shareholders (negative). The continuation of an established financing method suggests stability rather than a significant positive or negative surprise.

Positives

• Provides Cadrenal Therapeutics with a flexible mechanism to raise up to an additional $1,770,028 in capital.
• The company has already successfully utilized this ATM agreement to raise $10,005,300, demonstrating its effectiveness as a financing tool.
• The company maintains control over the timing and pricing of share sales, allowing for opportunistic capital raising.

Negatives

• The sale of additional common stock under the ATM program will result in dilution for existing shareholders.
• The 3.0% commission paid to H.C. Wainwright & Co., LLC reduces the net proceeds received by the company from the offering.

Risks

• The ATM Agreement may be terminated by either the company or H.C. Wainwright & Co., LLC under certain circumstances, including a material adverse change in the company, which could impact future capital raising efforts.
• The market price of the common stock could fluctuate, potentially affecting the amount of capital that can be raised and the extent of dilution.

Future Outlook

The company intends to continue utilizing its At-the-Market offering program to raise capital opportunistically, with the flexibility to set parameters for sales, including volume and minimum price, and the ability to suspend sales at any time.

Management Comments

• The company has no obligation to sell any shares under the ATM Agreement, and may at any time suspend solicitation and offers under the ATM Agreement.

Industry Context

At-the-Market (ATM) offerings are a common and flexible capital-raising tool, particularly for smaller biotechnology or pharmaceutical companies like Cadrenal Therapeutics, which often require ongoing funding for research, development, and operational expenses. This method allows companies to tap into public markets gradually, minimizing immediate dilution compared to a large secondary offering, and raising capital as needed without significant upfront costs or market disruption.

Comparison to Industry Standards

• The use of an ATM offering is a standard financing strategy for publicly traded companies, especially those in the biotechnology sector, to access capital efficiently.
• The 3.0% commission rate for the sales agent, H.C. Wainwright & Co., LLC, is within the typical range for such agreements in the industry, which often fall between 2% and 5%.
• The flexibility to control sale parameters and suspend the offering is a standard feature of ATM agreements, aligning with best practices for managing market impact and capital needs.

Stakeholder Impact

• Shareholders: Potential dilution of ownership percentage and earnings per share due to the issuance of new common stock.
• Company Operations: Provides additional capital to fund ongoing operations, research, and development, supporting the company's strategic objectives.

Next Steps

• The company may continue to offer and sell shares of common stock under the ATM Agreement up to the remaining capacity of $1,770,028.
• H.C. Wainwright & Co., LLC will continue to use commercially reasonable efforts to sell shares as directed by the company.

Key Dates

Recommendation

The filing details a standard At-the-Market equity offering, a common financing tool for growth-stage companies. While it provides necessary capital for operations, it also introduces potential dilution for existing shareholders. This is a routine event for companies in this sector and does not present new information that would significantly alter the fundamental investment thesis, warranting a "hold" recommendation.

Keywords

Cadrenal Therapeutics, CVKD, ATM offering, At-the-Market, capital raise, common stock, equity financing, H.C. Wainwright, SEC filing, Form 8-K, dilution